Forecast

The analysts' average price target is +1.152,42€ (+13,51%). The median is +1.168,20€ (+15,06%).

Buy	33
Hold	9
Sell	3

News Go to news feed

Eli Lilly: Zepbound reduces costs for over-55s and strengthens reimbursement position

Zepbound reduces monthly costs for patients aged 55 and older by up to $607. Fewer hospital stays offset Medicare expenditures from the sixth month onward. The study data improve Eli Lilly’s negotiating position on reimbursement; the business model continues to rely on profitable GLP-1/GIP agonists to treat metabolic diseases. » More on finanzen.net
Eli Lilly and Company: study shows Zepbound reduces healthcare costs in people over 55

A retrospective real-world study of 15,843 adults over 55 years old with obesity/overweight found that continued use of Zepbound, compared with untreated controls, was associated with lower healthcare costs and fewer hospital admissions and emergency department visits. After six months costs were up to 15% lower (up to $181 per patient per month), and after twelve months up to 38% lower (up to $607 per patient per month). The study excluded Zepbound medication costs, so the reported savings represent potential offsets against treatment costs, not the net cost impact. » More on de.investing.com
Eli Lilly launches weight-loss pill Foundayo in the UK

Eli Lilly has introduced the oral weight-loss pill Foundayo (active ingredient orforglipron) in the United Kingdom; the UK is the first country in Europe where the tablet is available. After MHRA approval on August 10, Foundayo will be offered on private prescription, while an assessment by NICE for possible inclusion in the NHS is ongoing. The price is expected to be between £100 and £120 per month, significantly cheaper than Lilly’s Mounjaro injection; EU approval is still under review. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Eli Lilly & Co has already paid 2,99€ in dividends. The last payout was in June.

Financials

In the last quarter, Eli Lilly & Co had revenue of 20.13b€ and net profit of 6.22b€

(EUR)	Jun 2026	YoY
Revenue	+20.13b	52,51%
Gross profit	+17.27b	55,24%
Net profit	+6.22b	29,45%
EBITDA	+8.10b	27,27%

Fundamentals

Metric	Value
Market capitalization	+997.80b€
Number of shares	941.74m
52-week high/low	+1.110,35€ - +611,63€
Dividend yield	+0,54%
Dividends TTM	+5,55€
Next dividend	+1,48€
Beta	0,51
P/E ratio	+41,32
PEG ratio	+0,44
P/B ratio	+32,49
P/S ratio	+14,58

Company profile

Eli Lilly and Company erforscht, entwickelt und vermarktet weltweit Humanarzneimittel. Es bietet Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, Insulin Lispro, Insulin Lispro Protamin, Insulin Lispro Mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R und Humulin U-500 für Diabetes; und Jardiance, Trajenta und Trulicity für Typ-2-Diabetes. Das Unternehmen bietet Alimta für nicht-kleinzelligen Lungenkrebs (NSCLC) und bösartiges Pleuramesotheliom; Cyramza für metastasierenden Magenkrebs, Adenokarzinom des gastroösophagealen Übergangs, metastasierenden NSCLC, metastasierenden kolorektalen Krebs und hepatozelluläres Karzinom; Erbitux für kolorektale Karzinome und verschiedene Kopf- und Halskrebsarten; Retevmo für metastasierten NSCLC, medullären Schilddrüsenkrebs und Schilddrüsenkrebs; Tyvyt für rezidivierte oder refraktäre klassische Hodgkin-Lymphome und nicht-squamösen NSCLC; und Verzenio für HR+, HER2- metastasierten Brustkrebs, knotenpositiven und frühen Brustkrebs. Es bietet Olumiant für rheumatoide Arthritis und Taltz für Plaque-Psoriasis, psoriatische Arthritis, ankylosierende Spondylitis und nicht-radiographische axiale Spondylarthritis. Das Unternehmen bietet Cymbalta für depressive Störungen, diabetische periphere neuropathische Schmerzen, generalisierte Angststörungen, Fibromyalgie und chronische Muskel-Skelett-Schmerzen; Emgality für Migräne-Prävention und episodische Cluster-Kopfschmerzen; und Zyprexa für Schizophrenie, bipolare Störung und bipolare Erhaltung. Seine Bamlanivimab und Etesevimab und Bebtelovimab für COVID-19; Cialis für erektile Dysfunktion und benigne Prostatahyperplasie; und Forteo für Osteoporose. Das Unternehmen arbeitet mit der Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., AbCellera Biologics Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc. und Foghorn Therapeutics Inc. zusammen. Eli Lilly and Company wurde 1876 gegründet und hat seinen Hauptsitz in Indianapolis, Indiana.

Name	Eli Lilly & Co
CEO	David A. Ricks
Headquarters	Indianapolis, in USA
Website	lilly.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	06/01/1972
Employees	50.000